Q3 2018

Filed Nov 14, 2018 · 10-Q · 45 days after period end · 0001564590-18-029562

Q3 2018 · 10-Q

Revenue

$5.82M

−5.6% vs Q3 2017

Net Income

-$12.56M

N/M vs Q3 2017

EPS Diluted

-$0.56

N/M vs Q3 2017

Operating Income-$12,127,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2018	Q3 2017	Q3 2016	Q3 2015
Revenue	$5.82M	$6.17M	$2.82M	$6.56M
Net Income	-$12.56M	$37.87M	-$71.74M	-$12.68M
EPS Diluted	-$0.56	$1.75	-$3.55	-$0.63

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR